FDA Approves SCENESSE® For Genetic Disorder
October 08, 2019 19:11 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which...
CLINUVEL delivers second positive financial result
August 29, 2018 06:52 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 29, 2018 (GLOBE NEWSWIRE) -- EXECUTIVE SUMMARY – FINANCIAL YEAR 01 JULY TO 30 JUNE 2017/182016/17ChangeTotal Revenues$25.750m$16.984m52%Net profit before income tax...
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
June 25, 2018 06:00 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare...
Clinuvel to file new drug with FDA
July 18, 2016 08:11 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, July 18, 2016 (GLOBE NEWSWIRE) -- Clinuvel Pharmaceuticals (ASX:CUV) (OTC:CLVLY) (XETRA:UR9) today announced that the US Food and Drug Administration (FDA) has...